FDA Accepts Investigational New Drug Application for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration with Intellia Therapeutics

Gene editing

Home » Emerging technologies » Gene editing » Page 2

Mammoth Biosciences Strengthens Executive Management With Biotech Veterans, Peter Nell and Ted Tisch

GenEdit and Editas Medicine Enter into Exclusive License and Collaboration Agreement for Nanoparticle Gene Therapy Delivery

Inscripta Raises $125M in Series D Financing to Accelerate Commercialization of Revolutionary Digital Genome Engineering Platform

Cyrus Biotechnology and the Broad Institute of MIT and Harvard Launch Multi-Target Collaboration to Develop Optimized CRISPR Gene Editing Technology

Caribou Biosciences Announces New Methods to Harness Type I CRISPR-Cas Systems for Genome Engineering in Human Cells

Inscripta

Video: Leveraging the power of digital genome engineering – Inscripta Workshop at SynBioBeta 2019

eGenesis Announces $100 Million Series B Financing

Inscripta

Video: Genome-scale mapping of genotype – Inscripta Workshop at SynBioBeta 2019

CRISPR

Fast-forward 10 years from now. What does the CRISPR genome editing field look like to you?

Beam Therapeutics Announces Collaboration and Exclusive License Agreement with Prime Medicine for Prime Editing Technology